Meifeng Tu

2.4k total citations
65 papers, 747 citations indexed

About

Meifeng Tu is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Meifeng Tu has authored 65 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pathology and Forensic Medicine, 26 papers in Oncology and 15 papers in Hematology. Recurrent topics in Meifeng Tu's work include Lymphoma Diagnosis and Treatment (34 papers), Viral-associated cancers and disorders (13 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Meifeng Tu is often cited by papers focused on Lymphoma Diagnosis and Treatment (34 papers), Viral-associated cancers and disorders (13 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Meifeng Tu collaborates with scholars based in China, Ethiopia and United States. Meifeng Tu's co-authors include Ningjing Lin, Lingyan Ping, Zhitao Ying, Wen Zheng, Xiaopei Wang, Yuqin Song, Weiping Liu, Yan Xie, Jun Zhu and Lijuan Deng and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Meifeng Tu

61 papers receiving 737 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Meifeng Tu China 12 471 313 200 126 110 65 747
Beatrice Casadei Italy 14 294 0.6× 336 1.1× 98 0.5× 94 0.7× 95 0.9× 84 662
Jennifer A. Kanakry United States 14 532 1.1× 306 1.0× 195 1.0× 196 1.6× 58 0.5× 51 769
Sumana Devata United States 15 347 0.7× 279 0.9× 267 1.3× 175 1.4× 144 1.3× 52 778
Chaitra S. Ujjani United States 15 622 1.3× 487 1.6× 156 0.8× 62 0.5× 97 0.9× 92 855
Cyrus Sayehli Germany 14 499 1.1× 231 0.7× 245 1.2× 62 0.5× 218 2.0× 37 831
Zhitao Ying China 14 502 1.1× 382 1.2× 171 0.9× 41 0.3× 171 1.6× 73 797
James Weisberger United States 15 266 0.6× 363 1.2× 104 0.5× 118 0.9× 80 0.7× 28 662
Ingrid Kuehnle United States 12 601 1.3× 155 0.5× 157 0.8× 225 1.8× 192 1.7× 15 1.1k
Rocı́o Hassan Brazil 17 582 1.2× 447 1.4× 344 1.7× 116 0.9× 113 1.0× 54 979
Lara Mussolin Italy 20 337 0.7× 610 1.9× 240 1.2× 131 1.0× 409 3.7× 73 1.2k

Countries citing papers authored by Meifeng Tu

Since Specialization
Citations

This map shows the geographic impact of Meifeng Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meifeng Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meifeng Tu more than expected).

Fields of papers citing papers by Meifeng Tu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meifeng Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meifeng Tu. The network helps show where Meifeng Tu may publish in the future.

Co-authorship network of co-authors of Meifeng Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Meifeng Tu. A scholar is included among the top collaborators of Meifeng Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meifeng Tu. Meifeng Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Yanfei, Lingyan Ping, Yuqin Song, et al.. (2024). Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial. BMC Medicine. 22(1). 107–107. 2 indexed citations
2.
Ying, Zhitao, Ting He, Shanzhao Jin, et al.. (2022). A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. Chinese Journal of Cancer Research. 34(1). 53–62. 5 indexed citations
3.
4.
Dong, Xifeng, et al.. (2021). Primary mediastinal large B cell lymphoma. Thoracic Cancer. 12(21). 2831–2837. 8 indexed citations
5.
6.
Liu, Yalu, Lijuan Deng, Lingyan Ping, et al.. (2019). ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma. Cancer Cell International. 19(1). 32–32. 23 indexed citations
7.
Wang, Xiaopei, Yan Xie, Weiping Liu, et al.. (2018). Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas. International Journal of Medical Sciences. 15(9). 867–874. 11 indexed citations
8.
Zheng, Wen, Yuhuan Gao, Xiaoyan Ke, et al.. (2018). PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. BMC Cancer. 18(1). 910–910. 8 indexed citations
9.
Cai, Qingqing, Meifeng Tu, Zijun Y. Xu‐Monette, et al.. (2017). NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Modern Pathology. 30(6). 854–876. 14 indexed citations
10.
Ying, Zhitao, Lan Mi, Xuejuan Wang, et al.. (2017). Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation. Chinese Journal of Cancer Research. 29(6). 561–571. 3 indexed citations
11.
Zheng, Wen, Hanyun Ren, Xiaoyan Ke, et al.. (2017). PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma. Chinese Journal of Cancer Research. 29(1). 66–74. 9 indexed citations
12.
Jia, Jing, Yuqin Song, Ningjing Lin, et al.. (2016). Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome. Annals of Hematology. 95(12). 2023–2031. 29 indexed citations
13.
Song, Yuqin, et al.. (2016). DICEレジメンによる97例の再発/難治性非ホジキンリンパ腫患者の治療効果と生存分析【JST・京大機械翻訳】. 37(9). 790–794. 1 indexed citations
14.
Xie, Yan, Yuntao Zhang, Wen Zheng, et al.. (2015). Outcomes of dose-adjusted Berlin–Frankfurt–Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma. Medical Oncology. 32(4). 110–110. 6 indexed citations
15.
Cao, Xin, Qing Ye, Robert Z. Orlowski, et al.. (2015). Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology & Oncology. 8(1). 74–74. 16 indexed citations
16.
Ping, Lingyan, Ning Ding, Yunfei Shi, et al.. (2014). [Clinical characteristics and prognosis analysis of patients with LMP-1 positive Hodgkin's lymphoma after EBV infection].. PubMed. 22(1). 78–84. 4 indexed citations
17.
Wang, Huaquan, Meifeng Tu, Rong Fu, et al.. (2014). The Clinical and Immune Characteristics of Patients with Hepatitis-Associated Aplastic Anemia in China. PLoS ONE. 9(5). e98142–e98142. 27 indexed citations
18.
Zhu, Jun, Wen Zheng, Weiping Liu, et al.. (2014). Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. Cancer Cell International. 14(1). 5–5. 5 indexed citations
19.
Shao, Zonghong, Meifeng Tu, Huaquan Wang, et al.. (2011). Circulating myeloid dendritic cells are increased in individuals with severe aplastic anemia. International Journal of Hematology. 93(2). 156–162. 35 indexed citations
20.
Xie, Yan, Wen Zheng, Yuntao Zhang, et al.. (2009). Clinical observation on rituximab combined with chemotherapy in the treatment of diffused large B cell lymphoma.. Tumori. 29(1). 53–57.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beatrice Casadei Breakdown of academic impact, for papers by Jennifer A. Kanakry Breakdown of academic impact, for papers by Sumana Devata Breakdown of academic impact, for papers by Chaitra S. Ujjani Breakdown of academic impact, for papers by Cyrus Sayehli Breakdown of academic impact, for papers by Zhitao Ying Breakdown of academic impact, for papers by James Weisberger Breakdown of academic impact, for papers by Ingrid Kuehnle Breakdown of academic impact, for papers by Rocı́o Hassan Breakdown of academic impact, for papers by Lara Mussolin
Rankless by CCL
2026